DMPS can reverse the features of severe mercury vapor-induced neurological damage DMPS and mercury vapor poisoning

Clinical Toxicology

Volumn 47, Issue 9, 2009, Pages 894-898

  Bradberry, Sally M ^a,b   Sheehan, Timothy M T ^a   Barraclough, Christopher R ^c   Vale, J Allister ^a,b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

DPMS; Mercury vapor; Neurological features; Unithiol

Indexed keywords

CALCIUM; COPPER; MAGNESIUM; MERCURY; UNITHIOL; ZINC;

ADULT; ARTICLE; CASE REPORT; CHELATION THERAPY; HANDWRITING; HEADACHE; HUMAN; LETHARGY; MALE; MERCURIALISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOMETRY; SLURRED SPEECH; TREMOR; VISUAL FIELD;

ADMINISTRATION, ORAL; ADULT; ANTIDOTES; CHELATING AGENTS; HUMANS; INHALATION EXPOSURE; JEWELRY; MALE; MERCURY POISONING; OCCUPATIONAL EXPOSURE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITHIOL;

EID: 70350441414     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650903333812     Document Type: Article

References (13)

1. Battistone GC, Miller RA, Rubin M. The use of 2,3-dimercaptopropane sodium sulfonate (DMPS) in mercury chelation therapy. In: Brown SS, ed. Clinical Chemistry and Chemical Toxicology of Metals. Amsterdam: Elsevier/North Holland Biomedical Press, 1977:221-224.
2. Torres-Alanís O, Garza-Ocañas L, Pineyro-Lopez A. Evaluation of urinary mercury excretion after administration of 2,3-dimercapto-1- propanesulfonic acid to occupationally exposed men. J Toxicol Clin Toxicol 1995; 33:717-720.
3. Nerudová J, Cábelková Z, Frantík E, Lukás E, Urban P, Bláha K, Pelclová D, Lebedová J, Cikrt M. Mobilization of mercury by DMPS in occupationally exposed workers and in model experiments on rats: evaluation of body burden. Int J Occup Med Environ Health 2000; 13:131-146.
4. Nielsen JB, Andersen O. Effect of four thio-containing chelators on disposition of orally administered mercuric chloride. Hum Exp Toxicol 1991; 10:423-430.
5. Buchet JP, Lauwerys RR. Influence of 2,3-dimercaptopropane-1- sulfonate and dimercaptosuccinic acid on the mobilization of mercury from tissues of rats pretreated with mercuric chloride, phenylmercury acetate or mercury vapors. Toxicology 1989; 54:323-333.
6. Aposhian HV, Morgan DL, Queen HLS, Maiorino RM, Aposhian MM. Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to mercury vapor. J Toxicol Clin Toxicol 2003; 41:339-347.
7. Aaseth J. Recent advance in the therapy of metal poisonings with chelating agents. Hum Toxicol 1983; 2:257-272.
8. Campbell JR, Clarkson TW, Omar MD. The therapeutic use of 2,3- dimercaptopropane-1-sulfonate in two cases of inorganic mercury poisoning. JAMA 1986; 256:3127-3130.
9. Corns WT, Stockwell PB, Jameel M. Rapid method for the determination of total mercury in urine samples using cold vapour atomic fluorescence spectrometry. Analyst 1994; 119:2481-2484.
10. Planas-Bohne F. Effect of 2,3-dimercaptopropane-1-sulfonate and dimercaptosuccinic acid on the distribution and excretion of mercuric chloride in rats. Toxicology 1981; 10:275-278.
11. Flanagan RJ, Jones AL. Antidotes. London, Taylor & Francis, 2001.
12. Dart RC, Hurlbut KM, Maiorino RM, Mayersohn M, Aposhian HV, Hassen LVB. Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. J Pediatr 1994; 125:309-316.
13. Torres-Alanís O, Garza-Ocañas L, Bernal MA, Piñeyro-López A. Urinary excretion of trace elements in humans after sodium 2,3-dimercaptopropane- 1-sulfonate challenge test. J Toxicol Clin Toxicol 2000; 38:697-700.